Scientists at St. Jude Children's Research Hospital have discovered that the shape of a protein on the surface of pneumonia bacteria helps these germs invade the human bloodstream. This finding, published Dec. 16 online by the EMBO Journal, could help scientists develop a vaccine that is significantly more effective at protecting children against the disease.
The St. Jude researchers determined the shape of a large, paddle-like molecule that Streptococcus pneumoniae bacteria use to latch onto cells lining the throat and lungs. The protein, called CbpA, binds to a molecule on the cell called pIgR, which takes antibodies from the bloodstream on one side of the cell and transports them to the other side. There it releases the antibody at the lining of the throat and lungs. If a pneumococcus bacterium is hovering on the lining of the respiratory tract, this germ binds to pIgR and pushes this antibody shuttle back through the cell to the bloodstream. Once at the other side of the cell, the pneumococcus breaks free of pIgR and enters the blood, where it can multiply and infect the body.
S. pneumoniae is the only bacterium known to use CbpA to invade human cells by binding to pIgR, according to Richard W. Kriwacki, Ph.D., associate member of St. Jude Structural Biology. Kriwacki is senior author of the EMBO Journal report. "The fact that we now know the structure of this important protein means we can begin to develop a vaccine that is more effective in children than those that are currently available," Kriwacki said.
Elaine Tuomanen, M.D., chair of Infectious Diseases and director of the Children's Infection Defense Center at St. Jude, is co-author of the EMBO Journal paper.
"Using CbpA as the key part of a new vaccine against S. pneumoniae would solve a problem that now hinders our ability to protect children from this infection," Tuomanen said.
Current pneumonia vaccines designed to protect adults against more than two dozen strains of S. pneumoniae do not work in young children. Adult vaccines are composed of pieces of carbohydrates naturally appearing on the surface of these bacteria. When used in a vaccine, these pieces of carbohydrate stimulate the immune system to make antibodies against the real carbohydrate targets on the bacteria. The problem with such vaccines is that the immune systems of very young children (younger than two years) do not naturally respond to carbohydrates. Pneumococcus vaccines for children must instead be modified by binding those carbohydrates to special proteins that stimulate the immune systems of young children.
"However such vaccines are so complex that they can carry carbohydrate targets for only a few specific strains of pneumonia bacteria," Tuomanen said. "So children are always under-protected, since there are so many different strains of these bacteria."
Knowing the shape of CbpA will guide researchers in their efforts to use part or all of this protein as the basis of a vaccine against S. pneumoniae.
"CbpA is a very large protein," Tuomanen said. "Now that we know what it looks like and how it's put together, we can pull it apart to see if smaller pieces of it can be used to make a vaccine that triggers production of antibodies against the CbpA. Since all the S. pneumoniae strains need CbpA to invade the bloodstream, we can widen the protection of a vaccine to all 90 types of pneumococcus by just adding CbpA, or a piece of CbpA."
The discovery of the structure of CbpA was a two-step process that included studies of how this protein works, followed by determination of its actual structure using powerful laboratory tools.